title: The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
abstract: BACKGROUND
  In this Tamoxifen Exemestane Adjuvant Multinational Japan sub-study, we evaluated the time course of changes in serum lipids in postmenopausal women with hormone-sensitive early breast cancer treated with exemestane, anastrozole, or tamoxifen for postoperative adjuvant therapy.
  
  
  METHODS
  A total of 154 breast cancer patients were assigned to receive exemestane, anastrozole, or tamoxifen in this randomized open-label study. Serum lipid parameters including triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured during 1 year of treatment.
  
  
  RESULTS
  TC and LDL-C rapidly decreased in patients treated with tamoxifen at 3 months. Compared with anastrozole and exemestane patients, TC and LDL-C were significantly lower at all assessment time points in tamoxifen patients (P < 0.05). TG increased in tamoxifen patients; it was significantly higher compared with exemestane patients at all assessment time points (P < 0.05). HDL-C slightly decreased in exemestane patients; it was significantly lower compared with anastrozole patients at 3 months and 1 year (P = 0.0179 and 0.0013, respectively).
  
  
  CONCLUSIONS
  Changes of lipid profiles in Japanese postmenopausal women treated with tamoxifen were relatively favorable, while exemestane and anastrozole had no clinically significant effect on the serum lipids.
authors.affiliation: Department of Breast and General Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan. y-hozumi@jichi.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Hozumi
authors.forename: K
authors.initials: K
authors.lastname: Suemasu
authors.forename: H
authors.initials: H
authors.lastname: Takei
authors.forename: T
authors.initials: T
authors.lastname: Aihara
authors.forename: M
authors.initials: M
authors.lastname: Takehara
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: S
authors.initials: S
authors.lastname: Ohsumi
authors.forename: N
authors.initials: N
authors.lastname: Masuda
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000077384:Anastrozole; D000730:Androstadienes / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D007564:Japan; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D009570:Nitriles / Q000627:therapeutic use*; D017698:Postmenopause / Q000097:blood; D013629:Tamoxifen / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D000730:Androstadienes; D047072:Aromatase Inhibitors; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D009570:Nitriles; D014230:Triazoles; D014280:Triglycerides; D013629:Tamoxifen; D000077384:Anastrozole; D002784:Cholesterol; C056516:exemestane